Last reviewed · How we verify
Spironolactone 200 mg
At a glance
| Generic name | Spironolactone 200 mg |
|---|---|
| Sponsor | Medical University of South Carolina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (PHASE4)
- Fibrosis and the Fontan (PHASE1, PHASE2)
- Transgender Estradiol Affirming Therapy (PHASE2)
- Drug-Drug Interaction Study in Trans Women Living With HIV (PHASE4)
- Spironolactone for Hidradenitis Suppurativa (PHASE4)
- Spironolactone for the Treatment of Melasma (PHASE1)
- Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men (PHASE2)
- Venetoclax and Lintuzumab-Ac225 in AML Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spironolactone 200 mg CI brief — competitive landscape report
- Spironolactone 200 mg updates RSS · CI watch RSS
- Medical University of South Carolina portfolio CI